 Home > Active Ingredient News > Antitumor Therapy > IMS 2022 Express MRD-Driven Instructive Value for Discontinuation of Maintenance Therapy in Multiple Myeloma

IMS 2022 Express MRD-Driven Instructive Value for Discontinuation of Maintenance Therapy in Multiple Myeloma

 Last Update: 2022-09-07
 Source: Internet
 Author: User

Tags

2 3 picture

1 4 benzoquinone

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Young patients with newly diagnosed multiple myeloma (NDMM) without comorbidities are often treated with induction therapy followed by high-dose melphalan combined with autologous hematopoietic stem cell transplantation (HDM/ASCT), followed by maintenance therapy until disease progression

01 Discontinuation of maintenance therapy in patients with persistent MRD-negative remission for 3 years: preliminary results from a phase II study

This year's IMS Annual Meeting reported interim results from a phase II study evaluating MRD-negative status after discontinuation of maintenance therapy in patients who had been in persistent MRD-negative remission for >3 years

From February 2020 to July 31, 2022, a total of 23 patients (15 in Phase 1; 8 in Phase 2) were enrolled

In Phase 1, 13/15 (83%) patients remained MRD-negative 12 months after discontinuation of maintenance therapy

Preliminary results from Phase 1 demonstrate the feasibility of discontinuing maintenance therapy in persistently MRD-negative patients (>3 years)

Persistent MRD and PET/CT negativity after ASCT as indicators of discontinuation of len maintenance therapy: results of a single-center prospective cohort study

Some researchers have also explored whether persistent MRD negativity can be used as an indicator of discontinuation of maintenance therapy in NDMM patients

Overall, 151 patients received induction therapy with a proteasome inhibitor-containing regimen and received HDM/ASCT

Our findings suggest that persistent MRD negativity after ASCT may be a safe and precise indicator of discontinuation of maintenance therapy

Reference source:

1.
Neha Korde, et al.
2022IMS.
Abstract#P-046.

2.
Panagiotis Malandrakis, et al.
2022IMS.
Abstract#P-051.

Edit: moly Reviewer: Quinta Typesetting: moly Execution: moly

Click "Read the original text" to see more content

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.